Oatly Group AB (publ)
28.9.2026 22:05:00 CEST | Globenewswire | Press release
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
MALMÖ, Sweden, September 28, 2026 – Oatly Group AB (publ) (Nasdaq: OTLY), the world’s original and largest oat drink company, will report financial results for the third quarter ended September 30, 2026, on Wednesday October 28, 2026 before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.
The conference call and simultaneous live webcast can be accessed on Oatly’s Investors website at https://investors.oatly.com under “Events.” The webcast will be archived for 30 days.
About Oatly
We are the world’s original and largest oat drink company. For over 30 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 60 countries globally.
For more information, please visit www.oatly.com.
Contacts
investors@oatly.com
press@oatly.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S24.10.2026 13:00:00 CEST | Press release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
ASYAD24.10.2026 12:47:36 CEST | Press release
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom